Blog
Planify news
MedGenome to launch genetic test to diagnose FSHD1
Link copied
MedGenome to launch genetic test to diagnose FSHD1
28 February 2023
MedGenome Labs has announced the launch of its Optical Genome Mapping Test (OGM) for diagnosing Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1) in India to provide an assessment of the genetic changes in patients with FSHD1. The test can detect large-scale insertions and duplications, as well as more subtle changes in DNA that can cause FSHD1.
MedGenome Labs has announced the launch of its Optical Genome Mapping Test (OGM) for diagnosing Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1) in India to provide an assessment of the genetic changes in patients with FSHD1. The test can detect large-scale insertions and duplications, as well as more subtle changes in DNA that can cause FSHD1.
Stay Connected, Stay Informed –
Join Our
Don’t miss out on exclusive updates, market trends, and real-time investment opportunities. Be the first to know about the latest unlisted stocks, IPO announcements, and curated Fact Sheets, delivered straight to your WhatsApp.